News and Trends 19 Nov 2016 Teaching Bacteria to make Living, Evolving Typography Ori Elisar is an Israeli artist working on Biodesign. His globally-acclaimed project uses bacteria to create living typography that changes over time to represent the evolution of the Hebrew language. The Living Language project uses Paenibacillus vortex bacteria to create living typography. To represent the evolution of the Hebrew language, the artist makes bacteria grow […] November 19, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2016 14 More Stories: CRISPR enters Humans, Biocartis makes a Splash Try as we might, we can’t cover all the biotech news out there. During the week, we only pick the top stories to keep you informed but not waste your time. Here’s a roundup of news that didn’t make the cut this week. Biocartis had a big week. The molecular diagnostics company raised €32.7M in an equity […] November 18, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2016 These Spider Silk Sneakers from Adidas Are Biodegradable Adidas just unveiled a biodegradable sneaker prototype made with a spider silk biomaterial manufactured by the German biotech AMSilk. Is this the beginning of a new era for sustainable biomaterials? AMSilk, located near Munich, is the world’s first biotech supplying synthetic silk biopolymers for textiles, cosmetics and medical devices. The company’s 100% biodegradable and vegan […] November 18, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2016 Microfluidics and Biosensors to tackle Antibiotic Resistance A little biosensor can analyze if there are antibiotics in your blood in 10 minutes. Developed by researchers from the University of Freiburg, the system could be used to develop a personalized course of antibiotics, but also to test food and water. The objective? Slow down the rise of multi-resistant bacteria. The World Antibiotic Awareness […] November 18, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2016 Can Oncolytic Viruses be the key to Treat Resistant Tumors? This week, we leave Belgium and keep traveling north to Oslo, where snow is starting to pack for the joy of skiers. Meanwhile, Targovax is there working hard to treat cancer with its immunotherapy pipeline. City: Oslo, Norway Founded: 2010 Employees: 20 – 30 Financial data: €12M raised in a private placement in July Mission: Targovax develops immuno-oncology […] November 18, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2016 Boehringer’s Biosimilar could take a Chunk out of the Cancer Market Boehringer Ingelheim is getting ready to launch a biosimilar for Roche’s cancer blockbuster Avastin as soon as the patent expires. Can it overcome the fierce competition in a market expected to grow to 50% of the drug market by 2020? Boehringer Ingelheim just announced results from a Phase I trial showing that its biosimilar candidate […] November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2016 Germany steps up the fight against the Most Painful Disease Grünenthal just acquired Thar Pharmaceuticals to pave the way towards treating complex regional pain syndrome (CRPS), considered one of the most painful conditions. Grünenthal, the company behind the thalidomide scandal in the 60s due to childbirth deformities, is now focusing on complex regional pain syndrome (CRPS), a rare orphan disease that causes prolonged and intense pain. In order […] November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2016 What’s in the Cards for a Biosimilar after it Launches As legal frameworks and regulatory pathways for biosimilars are in evolving all around the world, how will they affect the future of biosimilars? A biosimilar is a biological medicine that is similar to another already authorized for use, and they enter the market after the end of the patent of a biological drug. Biosimilars are […] November 17, 2016 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2016 Find Out what’s Hot in the Latin American Biotech scene You’ve probably heard about BIO-Europe, but what about BIO Latin America? The Latin American counterpart to BIO-Europe, Biolatam, was a success last year: over 250 attending companies from 20 countries participated in 400 one-on-one partnering meetings. Now, Biolatam kicks off in San Juan, Puerto Rico, on November 29th. It will feature over 300 dealmakers representing pharma, biotech and the accompanying […] November 17, 2016 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2016 UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy UniQure just announced a new R&D plan designed to save up to €27M over the next two years. Will the new strategy be enough to pull it out of its down spiral? UniQure is a Dutch biotech famous for launching Glybera, the first commercial gene therapy worldwide. However, the huge price of the treatment has […] November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2016 New Private Placement to Boost the Profitable Therapeutic Antibody Market MorphoSys has announced a private placement of shares to raise funds for its antibody therapy programs. With this push, the company is solidifying its position as a leader in the therapeutic antibody market, which is expected to reach €117B by 2021. MorphoSys, one of the few European billion euro biotechs, develops therapeutic antibodies for immuno-oncology, inflammatory […] November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2016 Microbiomics recruited for Immuno-Oncology in a Huge New Partnership What if the bacteria in your gut could help fight cancer? Enterome is partnering with Bristol-Myers Squibb to explore this possibility and develop microbiome-related therapeutics and diagnostics for immuno-oncology. Enterome, one of the coolest biotechs in Paris, specializes in the isolation of bacteria and microbial targets linked to immune modulation and inflammation. With an impressive […] November 16, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email